A study by Zhou et al. demonstrated that a histone deacetylase (HDAC) inhibitor, LBH589, resensitizes estrogen receptor (ER)-negative breast cancer cells to endocrine therapies by reactivating ER expression [25]. This evidence concerns the gene ESR1 and breast cancer.